MIRM Key Statistics, Chart & Performance
The current stock price of MIRM is 78.07 USD. In the past month the price increased by 9.97%. In the past year, price increased by 82.41%.
MIRM Latest News, Press Relases and Analysis
MIRM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About MIRM
Company Profile
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 355 full-time employees. The company went IPO on 2019-07-18. The firm is focused on the treatment of rare diseases affecting children and adults. The company has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The firm is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Company Info
MIRUM PHARMACEUTICALS INC
989 East Hillsdale Boulevard, Suite 300
Foster City CALIFORNIA 94404 US
CEO: Christopher Peetz
Employees: 355
Phone: 16506674085
MIRUM PHARMACEUTICALS INC / MIRM FAQ
What does MIRM do?
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 355 full-time employees. The company went IPO on 2019-07-18. The firm is focused on the treatment of rare diseases affecting children and adults. The company has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The firm is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
What is the current price of MIRM stock?
The current stock price of MIRM is 78.07 USD. The price decreased by -1.16% in the last trading session.
What is the dividend status of MIRUM PHARMACEUTICALS INC?
MIRM does not pay a dividend.
What is the ChartMill technical and fundamental rating of MIRM stock?
MIRM has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the number of employees for MIRUM PHARMACEUTICALS INC?
MIRUM PHARMACEUTICALS INC (MIRM) currently has 355 employees.
What is the market capitalization of MIRM stock?
MIRUM PHARMACEUTICALS INC (MIRM) has a market capitalization of 4.01B USD. This makes MIRM a Mid Cap stock.
What is the next earnings date for MIRM stock?
MIRUM PHARMACEUTICALS INC (MIRM) will report earnings on 2026-02-24, after the market close.
MIRM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to MIRM. When comparing the yearly performance of all stocks, MIRM is one of the better performing stocks in the market, outperforming 93.17% of all stocks.
MIRM Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to MIRM. The financial health of MIRM is average, but there are quite some concerns on its profitability.
MIRM Financial Highlights
Over the last trailing twelve months MIRM reported a non-GAAP Earnings per Share(EPS) of -0.86. The EPS increased by 57.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.3% | ||
| ROE | -14.26% | ||
| Debt/Equity | 1.06 |
MIRM Forecast & Estimates
16 analysts have analysed MIRM and the average price target is 104.35 USD. This implies a price increase of 33.66% is expected in the next year compared to the current price of 78.07.
For the next year, analysts expect an EPS growth of 78.72% and a revenue growth 51.86% for MIRM